



**NOTICE OF DETERMINATION  
CORE PARTICIPANT APPLICATION  
MODULE 1 - OFFICE OF THE CHIEF MEDICAL OFFICER**

**Introduction**

1. In my [Opening Statement](#) on 21 July 2022, I explained that Modules would be announced and opened in sequence, with those wishing to take a formal role in the Inquiry invited to apply to become Core Participants for each module. On the same day, the Inquiry opened Module 1 and invited anyone who wished to be considered as a Core Participant to that Module to submit an application in writing to the Solicitor to the Inquiry by 16 August 2022.
2. On 16th August 2022, the Inquiry received an application from the Office of the Chief Medical Officer (“the Office of the CMO” / “the Applicant”) for Core Participant status in Module 1. This Notice sets out my determination of the application.
3. The Inquiry has published the [Provisional Outline of Scope](#) for Module 1, which states that this module will examine the resilience and preparedness of the United Kingdom for a Coronavirus pandemic. Further modules will be announced and opened in due course, to address other aspects of the Inquiry’s Terms of Reference.

**Application**

4. Applications for Core Participant status are considered in accordance with Rule 5 of the Inquiry Rules 2006, which provides:

*5.—(1) The chairman may designate a person as a core participant at any time during the course of the inquiry, provided that person consents to being so designated.*



*(2) In deciding whether to designate a person as a core participant, the chairman must in particular consider whether—*

- (a) the person played, or may have played, a direct and significant role in relation to the matters to which the inquiry relates;*
- (b) the person has a significant interest in an important aspect of the matters to which the inquiry relates; or*
- (c) the person may be subject to explicit or significant criticism during the inquiry proceedings or in the report, or in any interim report.*

*(3) A person ceases to be a core participant on—*

- (a) the date specified by the chairman in writing; or*
- (b) the end of the inquiry.*

5. In accordance with the approach set out in my Opening Statement and the Inquiry's [Core Participant Protocol](#), I considered whether the application fulfils the requirements set out in Rule 5(2) in relation to the issues set out in the Provisional Outline of Scope for Module 1.

### **Summary of Application**

6. The application states that the Office of the CMO is comprised of the following individuals (in addition to the CMO Private Office): (1) Professor Sir Chris Whitty, the Chief Medical Officer for England ("CMO") since 2019; (2) Professor Sir Jonathan Nguyen-Van-Tam, a Deputy Chief Medical Officer ("DCMO") between 2017 and 2022; (3) Professor Dame Jenny Harries, a DCMO between 2019 and 2021; (4) Dr Thomas Waite, a DCMO from mid-2021 to date; and (5) Dr Aidan Fowler, a DCMO from 2018 to date.

7. The application states that the Office of the CMO: (a) Had an important role in explaining the characteristics and epidemiology of SARs-CoV-2 and Coronavirus disease; (b) Was and is an important component of the government structures and specialist bodies concerned with the response to a public health emergency; encompassing liaison with and providing advice to government departments, medical and scientific advisers within government, public health professionals at regional



levels and CMOs in the devolved administrations; (c) Would have been involved in pandemic planning. (d) Would have provided advice and views in relation to preparation including the response to previous epidemics and pandemics such as Ebola, influenza and Zika; (e) Was and is involved in the monitoring and communication of information and advice concerning emerging diseases; and (f) Has an important interest in the planning for future pandemics, including as head of the public health profession and the UK Government's principal medical adviser.

### **Decision for the Applicant**

8. I have considered with great care everything that is said in the application. Having done so, I am minded, in my discretion, to designate the Office of the CMO as a Core Participant in Module 1. I consider that the Applicant played, or may have played, a direct and significant role in relation to the UK's resilience and preparedness for the Covid-19 pandemic and that it has a significant interest in Module 1 of the Inquiry.

### **Legal Representation**

9. Applications for designation as the Recognised Legal Representative of a Core Participant are governed by Rules 6 and 7 of the Inquiry Rules 2006, which provide:

*6.—(1) Where—*

*(a) a core participant, other than a core participant referred to in rule 7; or*

*(b) any other person required or permitted to give evidence or produce documents during the course of the inquiry,*

*has appointed a qualified lawyer to act on that person's behalf, the chairman must designate that lawyer as that person's recognised legal representative in respect of the inquiry proceedings.*

*7.—(1) This rule applies where there are two or more core participants, each of whom seeks to be legally represented, and the chairman considers that—*

*(a) their interests in the outcome of the inquiry are similar;*

*(b) the facts they are likely to rely on in the course of the inquiry are similar; and*



*(c) it is fair and proper for them to be jointly represented.*

*(2) The chairman must direct that those core participants shall be represented by a single recognised legal representative, and the chairman may designate a qualified lawyer for that purpose.*

*(3) Subject to paragraph (4), any designation must be agreed by the core participants in question.*

*(4) If no agreement on a designation is forthcoming within a reasonable period, the chairman may designate an appropriate lawyer who, in his opinion, has sufficient knowledge and experience to act in this capacity.*

10. I am satisfied that the Office of the CMO has appointed Warrick Olsen of the Government Legal Department as its qualified lawyer in relation to this Module. I, therefore, designate Warrick Olsen as the Office of the CMO's recognised legal representative in accordance with Rule 6(1).

11. Directions will be given in relation to applications for an award under section 40(1)(b) of the Inquiries Act 2005 of expenses to be incurred in respect of legal representation, at the forthcoming preliminary hearing. I will determine any such applications in accordance with the provisions of section 40 of the Inquiries Act 2005, the Inquiry Rules 2006, the [Prime Minister's determination](#) under section 40(4) and the [Inquiry' Costs Protocol](#).

**Rt Hon Baroness Heather Hallett DBE**

**Chair of the UK Covid-19 Inquiry**

**7 September 2022**